BRPI0916363A2 - derivados de 4,5-di-hidro-oxazol-2-ila - Google Patents

derivados de 4,5-di-hidro-oxazol-2-ila

Info

Publication number: BRPI0916363A2
Authority: BR; Brazil
Prior art keywords: oxazol; dihydro; derivatives
Prior art date: 2008-07-24

Application number

BRPI0916363A

Other languages

English (en)

Inventor

Goergler Annick

Galley Guido

Groebke Zbinden Katrin

Norcross Roger

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-07-24

Filing date

2009-07-15

Publication date

2018-05-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41066683&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0916363(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-07-15 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2018-05-29 Publication of BRPI0916363A2 publication Critical patent/BRPI0916363A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/28—Nitrogen atoms not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Psychology (AREA)
Nutrition Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

BRPI0916363A 2008-07-24 2009-07-15 derivados de 4,5-di-hidro-oxazol-2-ila BRPI0916363A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08161060		2008-07-24
PCT/EP2009/059026 WO2010010014A1 (en)	2008-07-24	2009-07-15	4,5-dihydro-oxazol-2-yl derivatives

Publications (1)

Publication Number	Publication Date
BRPI0916363A2 true BRPI0916363A2 (pt)	2018-05-29

Family

ID=41066683

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0916363A BRPI0916363A2 (pt)	2008-07-24	2009-07-15	derivados de 4,5-di-hidro-oxazol-2-ila

Country Status (22)

Country	Link
US (2)	US20100041686A1 (pt)
EP (1)	EP2321287B1 (pt)
JP (1)	JP5547187B2 (pt)
KR (1)	KR101307007B1 (pt)
CN (1)	CN102083805A (pt)
AR (1)	AR072876A1 (pt)
AU (1)	AU2009273324A1 (pt)
BR (1)	BRPI0916363A2 (pt)
CA (1)	CA2728480A1 (pt)
CL (1)	CL2011000137A1 (pt)
CO (1)	CO6331336A2 (pt)
CR (1)	CR11843A (pt)
EC (1)	ECSP11010782A (pt)
ES (1)	ES2556633T3 (pt)
IL (1)	IL209423A0 (pt)
MA (1)	MA32486B1 (pt)
MX (1)	MX2011000464A (pt)
PE (1)	PE20110215A1 (pt)
RU (1)	RU2513086C2 (pt)
TW (1)	TW201008916A (pt)
WO (1)	WO2010010014A1 (pt)
ZA (1)	ZA201008657B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2328903B1 (en)	2008-09-11	2014-03-05	Amgen Inc.	Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
US8354441B2 (en)	2009-11-11	2013-01-15	Hoffmann-La Roche Inc.	Oxazoline derivatives
US9452980B2 (en)	2009-12-22	2016-09-27	Hoffmann-La Roche Inc.	Substituted benzamides
AU2011227501B9 (en)	2010-03-15	2013-08-22	Amgen Inc.	Amino -dihydrooxazine and amino - dihydrothiazine spiro compounds as Beta - secretase modulators and their medical use
WO2011115938A1 (en)	2010-03-15	2011-09-22	Amgen Inc.	Spiro-tetracyclic ring compounds as beta - secretase modulators
US9132136B2 (en) *	2010-08-02	2015-09-15	Hoffmann-La Roche Inc.	Pharmaceutical combination
US8673950B2 (en) *	2010-11-02	2014-03-18	Hoffmann-Laroche Inc.	Dihydrooxazol-2-amine derivatives
EP2673279A1 (en)	2011-02-07	2013-12-18	Amgen Inc.	5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
EP2758406A1 (en)	2011-09-21	2014-07-30	Amgen Inc.	Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2014078314A1 (en)	2012-11-15	2014-05-22	Amgen Inc.	Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
KR102415797B1 (ko)	2016-03-17	2022-07-04	에프. 호프만-라 로슈 아게	Taar의 작용제로서 활성을 갖는 5-에틸-4-메틸-피라졸-3-카복스아미드 유도체
EP3452473A1 (en) *	2016-05-04	2019-03-13	Purdue Pharma L.P.	Oxazoline pseudodimers, pharmaceutical compositions and the use thereof
US20190201410A1 (en) *	2016-06-02	2019-07-04	Purdue Pharma L.P.	Trace amine associated receptor 1 agonists and partial agonists for pain treatment

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2731471A (en) *		1956-01-17		Nxg hi
US2161938A (en) *	1934-07-31	1939-06-13	Soc Of Chemical Ind	Imidazolines
US2457047A (en) *	1946-02-13	1948-12-21	Monsanto Chemicals	2-(2'-thenyl)-4, 5-dihydroimidazoles and process for making the same
US2778836A (en) *	1954-04-02	1957-01-22	Union Chimique Belge Sa	Substituted 2-methyl-delta2 imidazolines
US2744909A (en) *	1955-06-27	1956-05-08	Bristol Lab Inc	2-(ortho-phenylbenzyl) imidazoline and acid addition salts
US2744910A (en) *	1955-06-27	1956-05-08	Bristol Lab Inc	2-(ortho-benzylbenzyl)-imidazoline and acid addition salts
US2919274A (en) *	1957-09-17	1959-12-29	Sahyun Melville	Amidines
DE1121054B (de) *	1960-11-23	1962-01-04	Merck Ag E	Verfahren zur Herstellung eines neuen Imidazolinderivates und dessen Saeureadditionssalzen
DE1150180B (de) *	1962-04-12	1963-06-12	Merck Ag E	Mittel zur Vorbehandlung der Haut fuer die Rasur
US3377247A (en) *	1967-04-28	1968-04-09	Dow Chemical Co	Antidepressant method
US3586695A (en) *	1968-01-26	1971-06-22	Dow Chemical Co	Substituted imidazolinyl indoles
US3577428A (en) *	1969-04-14	1971-05-04	Colgate Palmolive Co	2-amino-4-aryloxyalkyl-4-alkyl-2-oxazolines
BE754935A (fr) *	1969-08-13	1971-02-17	Hoechst Ag	2-(thienyl-3'-amino)-1,3-diazacycloalcenes et leur preparation
US3622579A (en) *	1969-08-28	1971-11-23	Boehringer Sohn Ingelheim	Derivatives of 2-anilino-1,3-diazacyclopentene-(2)
US3818094A (en) *	1969-08-28	1974-06-18	Boehringer Sohn Ingelheim	Hypotensive pharmaceutical compositions containing certain 2-anilino-1,3-diazacyclopentenes-(2)
US3660423A (en) *	1970-02-13	1972-05-02	Dow Chemical Co	2-(substituted benzyl)methyl-2-imidazolines
GB1333471A (en) *	1971-01-27	1973-10-10	Labaz	Imidazoline derivatives and process for preparing the same
US4125620A (en) *	1974-10-01	1978-11-14	Boehringer Ingelheim Gmbh	2-[(2',6'-Disubstituted-phenyl)-imino]-imidazolidines and salts thereof
US3992403A (en) *	1975-05-30	1976-11-16	Schering Corporation	2-Imidazolines and their use as hypoglycemic agents
GB1538097A (en) *	1976-01-26	1979-01-10	Lafon Labor	Substituted phenyl-amidines
US4323570A (en) *	1978-11-15	1982-04-06	Beiersdorf Aktiengesellschaft	Substituted aminopyrimidines
US4311840A (en) *	1980-11-13	1982-01-19	E. R. Squibb & Sons, Inc.	2,3,6,7-Tetrahydro-2-thioxo-4H-oxazolo[3,2-a]-1,3,5 triazin-4-ones
EP0096297B1 (de) *	1982-06-03	1988-06-15	F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft	Verfahren zur Herstellung von 1-Sulfo-2-oxoazetidinderivaten
DK302185A (da) *	1984-07-05	1986-01-06	Rolland Sa A	2-amino-oxazoliner samt fremgangsmaade til deres fremstilling
US4665095A (en) *	1985-12-11	1987-05-12	Abbott Laboratories	Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion
GB9425211D0 (en) *	1994-12-14	1995-02-15	Ucb Sa	Substituted 1H-imidazoles
DE19514579A1 (de) *	1995-04-20	1996-10-24	Boehringer Ingelheim Kg	Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
US5610174A (en) *	1995-06-02	1997-03-11	Synaptic Pharmaceutical Corporation	Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence
US5866579A (en) *	1997-04-11	1999-02-02	Synaptic Pharmaceutical Corporation	Imidazole and imidazoline derivatives and uses thereof
ATE293102T1 (de) *	1998-04-23	2005-04-15	Takeda Pharmaceutical	Naphthalene derivate ,ihre herstellung und verwendung
IL147921A0 (en) *	2002-01-31	2002-08-14	Abdulrazik Mohammad	A method for treating central nervous system disorders by ocular dosing
AU2005290008A1 (en) *	2004-09-24	2006-04-06	Allergan, Inc.	4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
BRPI0706759A2 (pt) *	2006-01-27	2011-04-05	Hofmann La Roche Ag F	Uso de derivados de 4-imidazol para distúrbios do cns
KR101275405B1 (ko) *	2007-02-02	2013-06-17	에프. 호프만-라 로슈 아게	중추 신경계 장애의 치료용 ｔａａｒ1 리간드로서 2-아미노옥사졸린

2009
- 2009-07-15 MX MX2011000464A patent/MX2011000464A/es not_active Application Discontinuation
- 2009-07-15 PE PE2011000063A patent/PE20110215A1/es not_active Application Discontinuation
- 2009-07-15 RU RU2011104433/04A patent/RU2513086C2/ru not_active IP Right Cessation
- 2009-07-15 ES ES09780600.4T patent/ES2556633T3/es active Active
- 2009-07-15 AU AU2009273324A patent/AU2009273324A1/en not_active Abandoned
- 2009-07-15 CN CN200980125666.7A patent/CN102083805A/zh active Pending
- 2009-07-15 WO PCT/EP2009/059026 patent/WO2010010014A1/en active Application Filing
- 2009-07-15 BR BRPI0916363A patent/BRPI0916363A2/pt not_active IP Right Cessation
- 2009-07-15 KR KR1020117001611A patent/KR101307007B1/ko not_active IP Right Cessation
- 2009-07-15 JP JP2011519122A patent/JP5547187B2/ja not_active Expired - Fee Related
- 2009-07-15 EP EP09780600.4A patent/EP2321287B1/en active Active
- 2009-07-15 CA CA2728480A patent/CA2728480A1/en not_active Abandoned
- 2009-07-17 US US12/504,702 patent/US20100041686A1/en not_active Abandoned
- 2009-07-22 TW TW098124766A patent/TW201008916A/zh unknown
- 2009-07-23 AR ARP090102799A patent/AR072876A1/es unknown
2010
- 2010-11-18 IL IL209423A patent/IL209423A0/en unknown
- 2010-11-25 CO CO10148408A patent/CO6331336A2/es not_active Application Discontinuation
- 2010-12-01 ZA ZA2010/08657A patent/ZA201008657B/en unknown
- 2010-12-13 CR CR11843A patent/CR11843A/es not_active Application Discontinuation
2011
- 2011-01-18 MA MA33533A patent/MA32486B1/fr unknown
- 2011-01-21 CL CL2011000137A patent/CL2011000137A1/es unknown
- 2011-01-24 EC EC2011010782A patent/ECSP11010782A/es unknown
2012
- 2012-03-02 US US13/410,315 patent/US20120165294A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CL2011000137A1 (es)	2011-07-15
AR072876A1 (es)	2010-09-29
KR20110020936A (ko)	2011-03-03
KR101307007B1 (ko)	2013-09-11
PE20110215A1 (es)	2011-03-31
AU2009273324A1 (en)	2010-01-28
JP2011528685A (ja)	2011-11-24
TW201008916A (en)	2010-03-01
WO2010010014A1 (en)	2010-01-28
EP2321287B1 (en)	2015-11-11
RU2011104433A (ru)	2012-08-27
ES2556633T3 (es)	2016-01-19
IL209423A0 (en)	2011-01-31
RU2513086C2 (ru)	2014-04-20
ZA201008657B (en)	2011-10-26
ECSP11010782A (es)	2011-02-28
CR11843A (es)	2011-02-16
CO6331336A2 (es)	2011-10-20
MX2011000464A (es)	2011-03-01
CN102083805A (zh)	2011-06-01
CA2728480A1 (en)	2010-01-28
MA32486B1 (fr)	2011-07-03
US20100041686A1 (en)	2010-02-18
EP2321287A1 (en)	2011-05-18
JP5547187B2 (ja)	2014-07-09
US20120165294A1 (en)	2012-06-28

Publication	Publication Date	Title
ATE555107T1 (de)	2012-05-15	2-aza-bicyclo-ä2,2,1-üheptan-derivate
BRPI0811718A2 (pt)	2014-11-18	Derivados de 3,3-espiroindolinona
BRPI0907563A2 (pt)	2015-08-04	Derivados de 4,5-di-hidro-xazol-2-il amina
BRPI0916363A2 (pt)	2018-05-29	derivados de 4,5-di-hidro-oxazol-2-ila
DE602008005634D1 (de)	2011-04-28	1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate
BRPI0816970A2 (pt)	2015-03-24	1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
ATE540040T1 (de)	2012-01-15	Dioxabicycloä3.2.1üoctan-2,3,4-triolderivate
BRPI0813707A2 (pt)	2014-12-30	Derivados de pirimidinil-piridazinona
BRPI0820112A2 (pt)	2015-05-05	Derivados de isoxazol-piridina
BRPI0809992A2 (pt)	2014-10-14	Derivados de pirrolopirimidina
BRPI0820113A2 (pt)	2015-05-05	Derivados de isoxazolo-piridazina
ATE481383T1 (de)	2010-10-15	3-aza-bicycloä3.1.0ühexanderivate
ATE469145T1 (de)	2010-06-15	4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
BRPI0923786A2 (pt)	2016-07-26	compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos
BRPI0812155A2 (pt)	2019-09-24	derivados de espiroindolinona
BRPI0817935A2 (pt)	2015-04-07	Derivados de biarila
BRPI0815717A2 (pt)	2015-02-10	Compostos de imidazopirazina.
BRPI0812518A2 (pt)	2015-03-31	Derivados de indazolamida
BRPI0814236A2 (pt)	2015-01-06	Derivados de quinazolinamida
BRPI0820649A2 (pt)	2015-06-16	Derivados de isoxazalo-pirazina
BRPI0913832A2 (pt)	2015-10-20	derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0915064A2 (pt)	2015-10-27	derivados de qunoxalinadiona
DK2344471T3 (da)	2013-10-07	7-piperidinalkyl-3,4-dihydroquinolon-derivat
DE602007001681D1 (de)	2009-09-03	1,3-dioxan-carboxylsäuren
BRPI0917446A2 (pt)	2015-12-22	derivados de acilaminobenzamida.

Legal Events

Date	Code	Title	Description
2018-06-12	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-06-19	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-05-14	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 10A ANUIDADE.
2019-09-03	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2523 DE 14-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.